Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.15M | -29.97M | -75.81M | -94.32M | -74.45M |
| Total Depreciation and Amortization | 128.00K | 156.00K | 172.00K | 177.00K | 193.00K |
| Total Amortization of Deferred Charges | 809.00K | 775.00K | 734.00K | 696.00K | 629.00K |
| Total Other Non-Cash Items | 11.16M | 16.48M | 18.13M | 17.43M | 19.21M |
| Change in Net Operating Assets | 4.05M | -1.56M | -5.95M | -8.91M | -9.04M |
| Cash from Operations | -5.00M | -14.12M | -62.73M | -84.93M | -63.46M |
| Capital Expenditure | -87.00K | -27.00K | -97.00K | -18.00K | -5.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -87.00K | -27.00K | -97.00K | -18.00K | -5.00K |
| Total Debt Issued | -- | -- | -- | -- | 24.75M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.27M | 293.00K | 80.00K | -- | 1.30M |
| Repurchase of Common Stock | -1.36M | -564.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.00K | -271.00K | 80.00K | -- | 26.05M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.19M | -14.41M | -62.75M | -84.95M | -37.42M |